Everolimus (EVE) is a mammalian target of rapamycin inhibitor (mTOR-I) widely used in transplantation that may determine some severe adverse events, including pulmonary fibrosis. The pathogenic mechanism of mTOR-I-associated pulmonary toxicity is still unclear, but epithelial to mesenchymal transition (EMT) of bronchial/pulmonary cells may play a role.
Product ID:
91669
Handle IRIS:
11562/939316
Last Modified:
November 15, 2022
Bibliographic citation:
Tomei, Paola; Masola, Valentina; Granata, Simona; Bellin, Gloria; Carratù, Pierluigi; Ficial, Miriam; Ventura, Valentina Anna; Onisto, Maurizio; Resta, Onofrio; Gambaro, Giovanni; Chilosi, Marco; Lupo, Antonio; Zaza, Gianluigi,
Everolimus-induced epithelial to mesenchymal transition (EMT) in bronchial/pulmonary cells: when the dosage does matter in transplantation«JN. JOURNAL OF NEPHROLOGY»
, vol. 29
, n. 6
, 2016
, pp. 881-891